Q1 2025 marked another strong quarter for life sciences VC financing, but the industry faces unique headwinds amid ongoing shake-ups in regulatory leadership and US trade relationships. Key takeaways for Q1 2025 include: •...more
It’s never too early to prepare an exit strategy, whether that exit is through an M&A, IPO or additional private financing. Albert Vanderlaan, Justin Yi and Samir Bakhru discuss the need for good corporate hygiene, process...more
This report series examines quarterly trends in life sciences venture investment. Key findings for Q3 2023 include:
Life sciences VC deal value in Q3 2023 totaled $7.7 billion, representing an uptick from last quarter...more
This edition of Orrick’s life sciences publication series breaks down the key drivers of venture investment in the life sciences industry, which is on track to set all-time records this year. Key findings include: • With...more